Le Lézard
Classified in: Health, Business
Subjects: PDT, LIC, MAT

Medical Marijuana, Inc. Announces Partnership with Peak Health to Sell First-Ever and Only Hops-Derived Cannabidiol (CBD) Product, ImmunAGtm


SAN DIEGO, June 26, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that it has partnered with Peak Health to distribute the first-ever, and only, hops (Kriya brand Humulus)-derived cannabidiol (CBD) product, ImmunAgtm. Medical Marijuana, Inc. is the exclusive distributor of ImmunAGtm and the product will be sold as Real Scientific Humulus Oil (RSHO-K) by Medical Marijuana, Inc.'s distribution subsidiary, HempMeds®.

ImmunAGtm is an extract of the Kriya brand Humulus plant, which is a variety of hops. Like hemp extract, the Kriya brand Humulus extract has a high concentration of CBD. Unlike CBD products derived from cannabis, which may contain trace amounts of Tetrahydrocannabinol (THC), ImmunAGtm contains no THC.

"Medical Marijuana, Inc. is a company of firsts and we're very proud to be the distributors of the first, and only, non-cannabis derived CBD product on the market," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "We believe that this partnership and this Humulus-derived, non-cannabis-based product will not only provide new evidence of the benefits of CBD, but will also help people understand the value of phytoceuticals. We also look to introduce and educate people/consumers on the new concept of 'bioactivity' into CBD's potential health and wellness benefits." 

Peak Health is a premier fitness and nutrition company in the United States. The company was founded by Dr. Avi Cohen and Dr. Bomi Joseph to conduct research and study the efficacy of plant compounds on human health. Dr. Joseph has a significant background in phytotherapy and has successfully developed a variety of world class phytoceutical products. He is a pioneer in the application of pharmaceutical science for phytotherapy and Traditional Complimentary Integrative Medicine.

"We're very excited to partner with such an established and prestigious company as Medical Marijuana, Inc.," said Director of Peak Health Dr. Bomi Joseph. "The company has established significant global reach and together we can reach even more people who want to try CBD but don't want to consume cannabis products."

Dr. Joseph continued, "There are many places in the world that do not allow cannabis. ImmunAG is a new option for them to get CBD today. People around the globe will now have access to a product that is licensed and approved as a food ingredient."

To learn more about the product or purchase ImmunAGtm, please visit https://www.medicalmarijuanainc.com/humulus/.

About Medical Marijuana, Inc.

We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.

About Peak Health

Peak Health Center is a 501(c)(3), Not-For-Profit Corporation, based out of Los Gatos, CA. Its charter is to improve human health, with the least use of pharmaceutical drugs. Its researchers from around the globe are volunteering efforts to enhance our knowledge of endogenous health and phytotherapy.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

LEGAL DISCLOSURE

Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil. In addition, the company now produces legal Humulus-based products, which are considered GRAS and a "food ingredient".

CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer CMW Media
P. 858-264-6600
[email protected] 
www.cmwmedia.com

 

SOURCE Medical Marijuana, Inc.


These press releases may also interest you

at 05:00
March 19, 2024   Amsterdam, the Netherlands ? Royal Philips , a global leader in health technology, today announced that it is one of the leading patent applicants at the European Patent Office (EPO). Building on more than 130 years of innovation,...

at 05:00
XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide a summary of Company's achievements in 2023 and...

at 05:00
Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to...

at 05:00
LifeSpan Vision Ventures, an investment firm specializing in longevity biotech investments, today announced an investment in SENISCA, an RNA therapeutics spinout from the University of Exeter. The company has developed proprietary technology that...

at 05:00
PharmaVentures is pleased to announce that it acted as the exclusive advisor to Phasefocus Holdings Limited on its sale to Bruker . Phasefocus is a privately held company that has leading expertise in imaging, image processing algorithms and imaging...

at 05:00
Herniated Disc Surgery Specialists of NYC,...



News published on and distributed by: